The interaction of genetic determinants in the outcome of HCV infection : evidence for discrete immunological pathways
© 2015 The Authors. Tissue Antigens published by John Wiley & Sons Ltd..
Diversity within the innate and adaptive immune response to hepatitis C is important in determining spontaneous resolution (SR) and treatment response. The aim of this study was to analyze how these variables interact in combination; furthering our understanding of the mechanisms that drive successful immunological clearance. Multivariate analysis was performed on retrospectively collected data for 357 patients previously genotyped for interferon (IFN)-λ3/4, killer cell immunoglobulin (KIR), human leukocyte antigen (HLA) class I and II and tapasin. High resolution KIR genotyping was performed for individuals with chronic infection and haplotypes determined. Outcomes for SR, IFN response and cirrhosis were examined. Statistical analysis included univariate methods, χ(2) test for trend, multivariate logistic regression, synergy and principal component analysis (PCA). Although KIR2DL3:HLA-C1C1 (P = 0.027), IFN-λ3/4 rs12979860 CC (P = 0.027), tapasin G in individuals with aspartate at residue 114 of HLA-B (TapG:HLA-B(114D) ) (P = 0.007) and HLA-DRB1*04:01 (P = 0.014) were associated with SR with a strong additive influence (χ(2) test for trend P < 0.0001); favorable polymorphisms did not interact synergistically, nor did patients cluster by outcome. In the treatment cohort, IFN-λ3/4 rs12979860 CC was protective in hepatitis C virus (HCV) G1 infection and KIR2DL3:HLA-C1 in HCV G2/3. In common with SR, variables did not interact synergistically. Polymorphisms predictive of viral clearance did not predict disease progression. In summary, different individuals resolve HCV infection using discrete and non-interacting immunological pathways. These pathways are influenced by viral genotype. This work provides novel insights into the complexity of the interaction between host and viral factors in determining the outcome of HCV infection.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2015 |
---|---|
Erschienen: |
2015 |
Enthalten in: |
Zur Gesamtaufnahme - volume:86 |
---|---|
Enthalten in: |
Tissue antigens - 86(2015), 4 vom: 18. Okt., Seite 267-75 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Hydes, T J [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 14.06.2016 Date Revised 13.12.2023 published: Print Citation Status MEDLINE |
---|
doi: |
10.1111/tan.12650 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM252860225 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM252860225 | ||
003 | DE-627 | ||
005 | 20231227125239.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2015 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/tan.12650 |2 doi | |
028 | 5 | 2 | |a pubmed24n1223.xml |
035 | |a (DE-627)NLM252860225 | ||
035 | |a (NLM)26381047 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Hydes, T J |e verfasserin |4 aut | |
245 | 1 | 4 | |a The interaction of genetic determinants in the outcome of HCV infection |b evidence for discrete immunological pathways |
264 | 1 | |c 2015 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.06.2016 | ||
500 | |a Date Revised 13.12.2023 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2015 The Authors. Tissue Antigens published by John Wiley & Sons Ltd. | ||
520 | |a Diversity within the innate and adaptive immune response to hepatitis C is important in determining spontaneous resolution (SR) and treatment response. The aim of this study was to analyze how these variables interact in combination; furthering our understanding of the mechanisms that drive successful immunological clearance. Multivariate analysis was performed on retrospectively collected data for 357 patients previously genotyped for interferon (IFN)-λ3/4, killer cell immunoglobulin (KIR), human leukocyte antigen (HLA) class I and II and tapasin. High resolution KIR genotyping was performed for individuals with chronic infection and haplotypes determined. Outcomes for SR, IFN response and cirrhosis were examined. Statistical analysis included univariate methods, χ(2) test for trend, multivariate logistic regression, synergy and principal component analysis (PCA). Although KIR2DL3:HLA-C1C1 (P = 0.027), IFN-λ3/4 rs12979860 CC (P = 0.027), tapasin G in individuals with aspartate at residue 114 of HLA-B (TapG:HLA-B(114D) ) (P = 0.007) and HLA-DRB1*04:01 (P = 0.014) were associated with SR with a strong additive influence (χ(2) test for trend P < 0.0001); favorable polymorphisms did not interact synergistically, nor did patients cluster by outcome. In the treatment cohort, IFN-λ3/4 rs12979860 CC was protective in hepatitis C virus (HCV) G1 infection and KIR2DL3:HLA-C1 in HCV G2/3. In common with SR, variables did not interact synergistically. Polymorphisms predictive of viral clearance did not predict disease progression. In summary, different individuals resolve HCV infection using discrete and non-interacting immunological pathways. These pathways are influenced by viral genotype. This work provides novel insights into the complexity of the interaction between host and viral factors in determining the outcome of HCV infection | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a IFN-λ3/4 | |
650 | 4 | |a hepatitis C | |
650 | 4 | |a immunogenetics | |
650 | 4 | |a interferon | |
650 | 4 | |a killer cell immunoglobulin receptors | |
650 | 4 | |a tapasin | |
650 | 7 | |a Histocompatibility Antigens Class I |2 NLM | |
650 | 7 | |a Histocompatibility Antigens Class II |2 NLM | |
650 | 7 | |a interferon-lambda, human |2 NLM | |
650 | 7 | |a IFNL4 protein, human |2 NLM | |
650 | 7 | |a Interleukins |2 NLM | |
650 | 7 | |a Membrane Transport Proteins |2 NLM | |
650 | 7 | |a Receptors, KIR |2 NLM | |
650 | 7 | |a tapasin |2 NLM | |
650 | 7 | |a Interferons |2 NLM | |
650 | 7 | |a 9008-11-1 |2 NLM | |
700 | 1 | |a Moesker, B |e verfasserin |4 aut | |
700 | 1 | |a Traherne, J A |e verfasserin |4 aut | |
700 | 1 | |a Ashraf, S |e verfasserin |4 aut | |
700 | 1 | |a Alexander, G J |e verfasserin |4 aut | |
700 | 1 | |a Dimitrov, B D |e verfasserin |4 aut | |
700 | 1 | |a Woelk, C H |e verfasserin |4 aut | |
700 | 1 | |a Trowsdale, J |e verfasserin |4 aut | |
700 | 1 | |a Khakoo, S I |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Tissue antigens |d 1971 |g 86(2015), 4 vom: 18. Okt., Seite 267-75 |w (DE-627)NLM00009482X |x 1399-0039 |7 nnns |
773 | 1 | 8 | |g volume:86 |g year:2015 |g number:4 |g day:18 |g month:10 |g pages:267-75 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/tan.12650 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 86 |j 2015 |e 4 |b 18 |c 10 |h 267-75 |